Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Systemic Intensification After CCRT in Locally Advanced Cervical Cancer

A critical review of post-CCRT intensification in locally advanced cervical cancer finds benefit with selected regimens, not broad escalation.

By Dr. Revathy Mohan V.R., MBBS · Nov 4, 2026 · 6 min read

Oncology·Lan GH

Neighborhood Disadvantage Linked to Multimorbidity in Childhood Cancer Survivors

A Lancet Global Health study examines how neighborhood disadvantage may shape multimorbidity progression in adult survivors of childhood…

Nov 4, 2026

Oncology·JAMA IM

Cardiovascular Specialist Referral Improves Lipids in Prostate Cancer Trial

Routine cardiovascular referral improved cholesterol control in men with prostate cancer, but did not lower major cardiovascular events…

Nov 4, 2026

Oncology·JTO

Durvalumab Cuts Extrathoracic Progression in Limited-Stage SCLC

ADRIATIC exploratory analysis found durvalumab lowered extrathoracic and brain progression after chemoradiotherapy in limited-stage small cell lung cancer.

Nov 3, 2026

Oncology·BMJ Open

Chidamide Combo Protocol Targets Relapsed Neuroblastoma in Children

A phase II Chinese study will test chidamide with dinutuximab beta, irinotecan, and temozolomide in relapsed or refractory…

Nov 3, 2026

Oncology·BMJ

Personalised care planning improves HNA delivery in treatable-but-not-curable cancer

A BMJ Open Quality pilot found the ARC clinic improved Holistic Needs Assessment completion, goal setting, and GP…

Nov 3, 2026

Oncology·JCO

Heidelberg Manifesto calls for stronger European cancer research infrastructure

European cancer leaders in Heidelberg outlined priorities for translational, prevention, clinical and digital cancer research through the Heidelberg…

Nov 3, 2026

Oncology·Blood

Novel Genomic Alterations in Relapsed Childhood B-ALL Identified by COG

A Children’s Oncology Group report examines novel genomic alterations in relapsed childhood B-ALL and why genomic profiling matters…

Nov 3, 2026

Oncology·medRxiv

Metformin and Breast Cancer Risk: Time Bias Rewrites the Signal

A new meta-analysis finds no breast cancer reduction with metformin once time-related bias is handled, while imeglimin still…

Nov 3, 2026

Oncology·bioRxiv

APR-246 and Novobiocin Show Synergy in TP53-Mutant AML

APR-246 combined with novobiocin killed TP53-mutant AML cells in preclinical models, with ferroptosis and apoptosis contributing to the…

Nov 3, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.